Long-term antiviral therapy appears to benefit only subgroups with zoster ophthalmicus

Zoster Eye Disease Study Long-term antiviral therapy appears to benefit only subgroups with zoster ophthalmicus

Two studies evaluating the benefits of 12 months of low-dose valacyclovir therapy for ophthalmic herpes zoster missed their primary endpoints. However, subgroups may benefit.